Overview

OTR Tablet 40 mg Fed-state Bioequivalence Study

Status:
Completed

Trial end date:
2017-11-06

Target enrollment:

Participant gender:

Summary

An open-label, single dose, randomized, cross-over study to confirm the bioequivalence (BE) of OTR tablet 40 mg and OXYCONTIN tablet 40 mg in a fed state in Chinese subjects with chronic pain.

Phase:

Phase 1

Details

Lead Sponsor:

Mundipharma (China) Pharmaceutical Co. Ltd

Treatments:

Oxycodone